AXQ Capital’s RAPT Therapeutics RAPT Stock Holding History

AXQ Capital’s Portfolio RAPT Stock Details RAPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-1,600	Closed	-$235K	–	515
2023 Q1	$235K	Buy	+1,600	New	+$324K	0.09%	370

Other funds holding RAPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

AXQ Capital's RAPT Position: Q2 2023 in Review

AXQ Capital sold out of RAPT Therapeutics (RAPT) in Q2 2023, closing a stake of 1,600 shares — an estimated $235K sold.

AXQ Capital first reported a position in RAPT in Q1 2023 and held it in 1 quarter. The position peaked at $235K in Q1 2023. 98 funds tracked by Wall St. Rank hold RAPT as of Q2 2023.

AXQ Capital reported no remaining RAPT Therapeutics position as of Q2 2023 after selling out during the quarter.
AXQ Capital sold 1,600 RAPT Therapeutics shares in Q2 2023, an estimated $235K.
AXQ Capital first reported a position in RAPT Therapeutics in Q1 2023 and held it in 1 quarter.
AXQ Capital's RAPT Therapeutics position peaked at $235K in Q1 2023.
98 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2023.

Based on AXQ Capital's 13F filing for Q2 2023, filed 11 Aug 2023.